Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, today announced that the company has acquired from Gilead Sciences, Inc. the worldwide license, including related regulatory filings and intellectual properties, to Gilead’s investigational molecule, GS 9191, for topical use. GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death. [More]

Driver Aric Almirola is lending his voice to a national public education program to raise awareness of actinic keratosis (AK) -- a potential early warning sign of skin cancer -- as well as the long-term consequences of sun damage over a lifetime. The national campaign, "Is it AK or OK?" is sponsored by Graceway Pharmaceuticals, LLC, in partnership with The Skin Cancer Foundation. [More]

Anadys Pharmaceuticals presented data from an in vitro study showing that the active metabolite of ANA773 promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, cytolysis of tumor cells and enhanced antibody-dependent cellular cytotoxicity (ADCC), during a poster presentation at the Annual Meeting of the American Association of Cancer Research (AACR) in Los Angeles. [More]

The US Food and Drug Administration has approved a new treatment for some people with a very common form of skin cancer. Imiquimod cream, sold as Aldara, can now be used to treat superficial basal cell carcinoma. [More]

3M announced today that the U.S. Food and Drug Administration (FDA) has approved the first prescription therapy in nearly a decade for the treatment of superficial basal cell carcinoma (sBCC), a type of nonmelanoma skin cancer. [More]

3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer. [More]